Empagliflozin for treating chronic heart failure with reduced ejection fraction (HFrEF)
NICE suggest that (1):
Study evidence supporting use of empagliflozin in HFrEF comes from the Emperor Reduced study where the authors concluded that (2):
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.